Gilead Sciences, Inc. (NASDAQ:GILD) Position Lessened by Aviance Capital Partners LLC

Aviance Capital Partners LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 75.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,218 shares of the biopharmaceutical company's stock after selling 15,684 shares during the quarter. Aviance Capital Partners LLC's holdings in Gilead Sciences were worth $585,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC grew its holdings in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares during the last quarter. Proficio Capital Partners LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $339,000. Steward Partners Investment Advisory LLC grew its holdings in shares of Gilead Sciences by 12.6% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 45,818 shares of the biopharmaceutical company's stock valued at $4,232,000 after purchasing an additional 5,116 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $207,340,000. Finally, Lindbrook Capital LLC grew its holdings in shares of Gilead Sciences by 9.6% during the fourth quarter. Lindbrook Capital LLC now owns 4,585 shares of the biopharmaceutical company's stock valued at $424,000 after purchasing an additional 403 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Cantor Fitzgerald assumed coverage on Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 target price for the company. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Oppenheimer decreased their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Finally, Morgan Stanley increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the sale, the chief financial officer owned 165,110 shares in the company, valued at $18,190,168.70. This represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the completion of the sale, the chief executive officer owned 615,725 shares of the company's stock, valued at $68,006,826.25. The trade was a 1.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold 58,500 shares of company stock worth $6,340,745 over the last quarter. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded down $0.70 on Monday, reaching $111.05. 2,292,822 shares of the company traded hands, compared to its average volume of 7,685,037. Gilead Sciences, Inc. has a fifty-two week low of $66.34 and a fifty-two week high of $119.96. The company's 50 day moving average is $107.02 and its 200-day moving average is $104.11. The stock has a market capitalization of $138.13 billion, a PE ratio of 23.38, a P/E/G ratio of 0.72 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The company had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the prior year, the firm earned ($1.32) EPS. The company's quarterly revenue was down .3% compared to the same quarter last year. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were issued a $0.79 dividend. The ex-dividend date was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.85%. Gilead Sciences's payout ratio is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.